我院艾滋病患者使用膦甲酸钠的不良反应分析
|
摘要
目的了解本院艾滋病患者近年来使用膦甲酸钠的不良反应(ADR)情况,为膦甲酸钠在艾滋病患者中的安全合理应用提供参考。方法收集整理本院2016年1月—2018年1月艾滋病患者使用膦甲酸钠后的29例ADR报告,对其进行统计分析。结果 29例ADR中男性18例,女性11例,19～50岁22例;艾滋病患者使用膦甲酸钠所致ADR主要表现为局部麻木,其次为恶心、呕吐;经过停药或对症处理后均好转,无后遗症或死亡病例发生。结论艾滋病患者使用膦甲酸钠后常因ADR而停药,影响疗效,临床应在合理使用的同时,加强监测并及时处理其ADR。
Objective To analyze foscarnet-induced adverse drug reactions(ADRs) in patients with acquired immunodeficiency syndrome(AIDS) in our hospital, and to provide reference for the rational use of foscarnet in AIDS patients. Methods Totally 29 foscarnet ADRs were reported and analyzed from January 2016 to January 2018. Results Of the 29 ADR, 18 were male patients and 11 female patients, mostly 19-50 years old. Regional numbness was the major clinical manifestation, followed by nausea and vomiting. After the withdrawal of foscarnet and symptomatic treatment, most symptoms disappeared. Conclusion Withdrawal of foscarnet is common among most AIDS patients due to ADRs, so we should pay more attention to foscarnet ADR in AIDS patients to ensure rational use.
Objective To analyze foscarnet-induced adverse drug reactions(ADRs) in patients with acquired immunodeficiency syndrome(AIDS) in our hospital, and to provide reference for the rational use of foscarnet in AIDS patients. Methods Totally 29 foscarnet ADRs were reported and analyzed from January 2016 to January 2018. Results Of the 29 ADR, 18 were male patients and 11 female patients, mostly 19-50 years old. Regional numbness was the major clinical manifestation, followed by nausea and vomiting. After the withdrawal of foscarnet and symptomatic treatment, most symptoms disappeared. Conclusion Withdrawal of foscarnet is common among most AIDS patients due to ADRs, so we should pay more attention to foscarnet ADR in AIDS patients to ensure rational use.
引文
[1]Gerard L,Ceron DS.Pharmacology and clinical use of foscarnet[J].Int J Antimicrob Ag,1995,5(4):209-217.
[2]Deray G,Martinez F,Katlama C,et al.Foscarnet nephrotoxicity:mechanism,incidence and prevention[J].Am JNephrol,1989,9(4):316-321.
[3]李俊萍.膦甲酸钠的研究现状及临床应用[J].天津医学,2002,6(14):12-13.
[4]WHO药品不良反应术语集累及的系统-器官代码检查目录[J].中国药物警戒,2007,1(4):58-64.
[5]王芳,郜桂菊,孙娜,等.95例艾滋病患者药物不良反应的分析[J].临床药物治疗杂志,2013,6(11):20-24.
[6]钟福华.艾滋病在中国的流行特点、原因与防治对策[J].预防医学情报杂志,2007,2(23):200-204.
[7]胡扬,刘一,刘水,等.北京地区2008~2014年膦甲酸钠不良反应分析[J].中国药学杂志,2015,18(50):1634-1638.
[8]Mehta U,Durrheim DN,Blockman M,et al.Adverse drug reactions in adult medical inpatients in a South African hospital serving a community with a high HIV/AIDSprevalence:prospective observational study[J].Br J Clin Pharmacol,2007,65(3):396-406.
[9]吴念宁,葛利辉,杜红,等.南宁地区HIV/AIDS患者药物不良反应报告分析[J].临床合理用药,2012,1A(5):11-12.
[10]周志平,陈威巍,汤勃,等.EB病毒感染及其相关性疾病[J].传染病信息,2013,1(26):57-60.
[11]戴欣,黄文祥.原发EB病毒感染诊治进展[J].现代临床医学,2015,2(41):103-106.
[12]Afshar K,Rao AP,Patel V,et al.Use of foscarnet therapy for EBV infection following control of PTLD with enhancement of cellular immunity in a lung-transplant recipient[J].J Transplant,2011,(2011):1-4.
[13]任晓蕾,黄婧,李玉珍.膦甲酸钠相关癫痫发作及肾损害[J].药物不良反应杂志,2010,144(12):239-245.
[14]汤仲明.2012年美国FDA批准药物简介[J].国际药学研究杂志,2013,1(40):111-123.
[15]王欣,王冰,徐明丽,等.膦甲酸钠注射液致急性肾功能衰竭1例[J].中国药物应用与监测,2016,5(13):324-326.
[16]Brett P,Lisa L,Anne A,et al.Safety and efficacy of foscarnet for the management of ganciclovir-resistant or refractory cytomegalovirus infections:A single-center study[J].Transpl Infect Dis,2018,20(2):e12852.
[17]叶敬伟,郭晓玲,李焱.膦甲酸钠氯化钠注射液在血液病合并EBV感染中的疗效和安全性分析[J].临床血液学杂志,2018,1(31):41-43.
[18]关欣,陈诗翔,徐敏丽,等.膦甲酸钠治疗112例带状疱疹的疗效和安全性回顾性分析[J].中国皮肤性病学杂志,2014,12(28):1238-1240.
[19]Zhou W,Sultana R,Diong C,et al.Long-term renal outcome after allogeneic hemopoietic stem cell transplant:A comprehensive analysis of risk factors in an Asian patient population[J].Clin Transplant,2017,31(4):e12920.
[20]王平,彭弘,楼方定,等.膦甲酸钠致低钙、低钾血症2例[J].中国医院药学杂志,2001,21(1):62.
[21]陈开杰,李小玲,张云琛.膦甲酸钠氯化钠注射液致四肢麻木1例[J].药物流行病学杂志,2017,26(2):149-150.
[2]Deray G,Martinez F,Katlama C,et al.Foscarnet nephrotoxicity:mechanism,incidence and prevention[J].Am JNephrol,1989,9(4):316-321.
[3]李俊萍.膦甲酸钠的研究现状及临床应用[J].天津医学,2002,6(14):12-13.
[4]WHO药品不良反应术语集累及的系统-器官代码检查目录[J].中国药物警戒,2007,1(4):58-64.
[5]王芳,郜桂菊,孙娜,等.95例艾滋病患者药物不良反应的分析[J].临床药物治疗杂志,2013,6(11):20-24.
[6]钟福华.艾滋病在中国的流行特点、原因与防治对策[J].预防医学情报杂志,2007,2(23):200-204.
[7]胡扬,刘一,刘水,等.北京地区2008~2014年膦甲酸钠不良反应分析[J].中国药学杂志,2015,18(50):1634-1638.
[8]Mehta U,Durrheim DN,Blockman M,et al.Adverse drug reactions in adult medical inpatients in a South African hospital serving a community with a high HIV/AIDSprevalence:prospective observational study[J].Br J Clin Pharmacol,2007,65(3):396-406.
[9]吴念宁,葛利辉,杜红,等.南宁地区HIV/AIDS患者药物不良反应报告分析[J].临床合理用药,2012,1A(5):11-12.
[10]周志平,陈威巍,汤勃,等.EB病毒感染及其相关性疾病[J].传染病信息,2013,1(26):57-60.
[11]戴欣,黄文祥.原发EB病毒感染诊治进展[J].现代临床医学,2015,2(41):103-106.
[12]Afshar K,Rao AP,Patel V,et al.Use of foscarnet therapy for EBV infection following control of PTLD with enhancement of cellular immunity in a lung-transplant recipient[J].J Transplant,2011,(2011):1-4.
[13]任晓蕾,黄婧,李玉珍.膦甲酸钠相关癫痫发作及肾损害[J].药物不良反应杂志,2010,144(12):239-245.
[14]汤仲明.2012年美国FDA批准药物简介[J].国际药学研究杂志,2013,1(40):111-123.
[15]王欣,王冰,徐明丽,等.膦甲酸钠注射液致急性肾功能衰竭1例[J].中国药物应用与监测,2016,5(13):324-326.
[16]Brett P,Lisa L,Anne A,et al.Safety and efficacy of foscarnet for the management of ganciclovir-resistant or refractory cytomegalovirus infections:A single-center study[J].Transpl Infect Dis,2018,20(2):e12852.
[17]叶敬伟,郭晓玲,李焱.膦甲酸钠氯化钠注射液在血液病合并EBV感染中的疗效和安全性分析[J].临床血液学杂志,2018,1(31):41-43.
[18]关欣,陈诗翔,徐敏丽,等.膦甲酸钠治疗112例带状疱疹的疗效和安全性回顾性分析[J].中国皮肤性病学杂志,2014,12(28):1238-1240.
[19]Zhou W,Sultana R,Diong C,et al.Long-term renal outcome after allogeneic hemopoietic stem cell transplant:A comprehensive analysis of risk factors in an Asian patient population[J].Clin Transplant,2017,31(4):e12920.
[20]王平,彭弘,楼方定,等.膦甲酸钠致低钙、低钾血症2例[J].中国医院药学杂志,2001,21(1):62.
[21]陈开杰,李小玲,张云琛.膦甲酸钠氯化钠注射液致四肢麻木1例[J].药物流行病学杂志,2017,26(2):149-150.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |